[Radiomodifying properties of the synthetic analog of prostaglandin F2 alpha-estrofan].
Estrofan (0.1 to 5 mg/kg) administered to rats and mice 5 min prior to gamma irradiation with doses of 8.5 to 9.5 Gy (LD90/30) increases the survival rate up to 30-40 per cent. The drug is ineffective when administered 30 and 60 min before irradiation.
Chernov
Iu N
IuN
Vasin
M V
MV
Semenova
L A
LA
D000818:Animals; D015237:Dinoprost; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D005260:Female; D005720:Gamma Rays; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008808:Mice, Inbred CBA; D011460:Prostaglandins F / Q000627:therapeutic use*; D011461:Prostaglandins F, Synthetic / Q000627:therapeutic use*; D011833:Radiation Injuries, Experimental / Q000188:drug therapy / Q000401:mortality; D011837:Radiation-Protective Agents / Q000627:therapeutic use*; D051381:Rats; D013997:Time Factors
D011460:Prostaglandins F; D011461:Prostaglandins F, Synthetic; D011837:Radiation-Protective Agents; D015237:Dinoprost
Radiomodifitsiruiushchie svoĭstva sinteticheskogo analoga prostaglandina F2 al'fa-éstrofana.